Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 2:15:5-12.
doi: 10.33393/dti.2021.2192. eCollection 2021 Jan-Dec.

Tamarind (Tamarindus indica L.) Seed a Candidate Protein Source with Potential for Combating SARS-CoV-2 Infection in Obesity

Affiliations
Review

Tamarind (Tamarindus indica L.) Seed a Candidate Protein Source with Potential for Combating SARS-CoV-2 Infection in Obesity

Ana H de A Morais et al. Drug Target Insights. .

Abstract

Introduction:: Obesity and coronavirus disease (COVID)-19 are overlapping pandemics, and one might worsen the other.

Methods:: This narrative review discusses one of the primary mechanisms to initiate acute respiratory distress syndrome, uncontrolled systemic inflammation in COVID-19, and presents a potential candidate for adjuvant treatment. Blocking the S protein binding to angiotensin-converting enzyme 2 (ACE-2) and the 3C-like protease (3CL pro) is an effective strategy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Results:: Host proteases such as FURIN, trypsin, and transmembrane serine protease 2 (TMPRSS) act in S protein activation. Tamarind trypsin inhibitor (TTI) shows several beneficial effects on the reduction of inflammatory markers (tumor necrosis factor α [TNF-α], leptin) and biochemical parameters (fasting glycemia, triglycerides, and very low-density lipoprotein [VLDL]), in addition to improving pancreatic function and mucosal integrity in an obesity model. TTI may inhibit the action of proteases that collaborate with SARS-CoV-2 infection and the neutrophil activity characteristic of lung injury promoted by the virus.

Conclusion:: Thus, TTI may contribute to combating two severe overlapping problems with high cost and social complex implications, obesity and COVID-19.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no conflicts of interest.

Figures

Fig. 1-
Fig. 1-. Obesity and associated comorbidities as risk factors for complications from SARS-CoV-2 infection, and hypothesis of the TTI mechanism of action. Obesity affects several organs, which have several responses, such as increased inflammation, changes in sensitivity and the action of hormones, dyslipidemia, and others. This metabolic deregulation favors increased expression of ACE-2, which is cleaved in the C-terminal segment by proteases such as TMPRSS2 and FURIN, and there is activation of the spike glycoprotein, so this process facilitates the entry of SARS-CoV-2 into the cells, causing viral infection. Also, 3CL pro is considered a key component in polyprotein processing and plays an important role in the replication and transcription of viral RNA. The TTI effects in in vitro and preclinical studies show several antiobesity and anti-inflammatory effects and appear to be possible inhibitors of the proteases TMPRSS2, FURIN, and 3CLpro.
ACE-2 = angiotensin-converting enzyme 2; CCK = cholecystokinin; FURIN = member of the mammalian prohormone-protein convertases family; HNE = human neutrophil elastase; IL-1β = interleukin 1-β; LPS = lipopolysaccharide; MCP-1 = monocyte chemoattractant protein 1; SREBP = sterol regulatory element-binding proteins; TG = triglyceride; TMPRSS2 = transmembrane serine protease 2; TNF-α = tumor necrosis factor α; TTI = trypsin inhibitor from tamarind; VLDL-c = very-low-density lipoprotein cholesterol; 3CL pro = 3C-like protease.

References

    1. Dietz W, Santos-Burgoa C. Obesity and its implications for COVID-19 Mortality. Obesity (Silver Spring). 2020;28(6):1005. doi: 10.1002/oby.22818. PubMed - DOI - PubMed
    1. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020;368(March):m1198. doi: 10.1136/bmj.m1198. PubMed - DOI - PubMed
    1. Callahan EA, editor. National Academies of Sciences and Medicine E, National Academies of Sciences, Engineering and M. Current Status and Response to the Global Obesity Pandemic: Proceedings of a Workshop—in Brief. The National Academies Press; 2019. ( ). - DOI - PubMed
    1. Del Rio C, Malani PN. COVID-19—new insights on a rapidly changing epidemic. JAMA. 2020;323(14):1339–1340. doi: 10.1001/jama.2020.3072. PubMed - DOI - PubMed
    1. Gupta R, Ghosh A, Singh AK, Misra A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr. 2020;14(3):211–212. doi: 10.1016/j.dsx.2020.03.002. PubMed - DOI - PMC - PubMed

LinkOut - more resources